ReviewChromosoma2012
Inner workings and regulatory inputs that control Polycomb repressive complex 2.
Review in Chromosoma, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03707782 (Mechanisms of Immune Deficiency), which is not on this map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mechanisms of Immune Deficiency
Who cites it
46 citing papers in PubMed.
- Article
- A conserved function of EZH2-PRC2 in repression of primitive endoderm fate in mouse and human pluripotent cells.Stem cell reports · 2025Article
- siRNA treatment targeting integrin α11 overexpressed via EZH2-driven axis inhibits drug-resistant breast cancer progression.Breast cancer research : BCR · 2024Article
- A putative role for lncRNAs in epigenetic regulation of memory.Neurochemistry international · 2021Review
- Enhancer of zeste homolog 2 contributes to apoptosis by inactivating janus kinase 2/ signal transducer and activator of transcription signaling in inflammatory bowel disease.World journal of gastroenterology · 2021Article
- The noncanonical role of EZH2 in cancer.Cancer science · 2021Review
- Reprogramming Müller Glia to Regenerate Retinal Neurons.Annual review of vision science · 2020Review
- Proteasomal Degradation of Enhancer of Zeste Homologue 2 in Cholangiocytes Promotes Biliary Fibrosis.Hepatology (Baltimore, Md.) · 2019Article
- Three additional patients with EED-associated overgrowth: potential mutation hotspots identified?Journal of human genetics · 2019Article
- Small Molecule Inhibitors of KDM5 Histone Demethylases Increase the Radiosensitivity of Breast Cancer Cells Overexpressing JARID1B.Molecules (Basel, Switzerland) · 2019Article
- Increased Extracellular Matrix Protein Production in Chronic Diabetic Complications: Implications of Non-Coding RNAs.Non-coding RNA · 2019Review
- Article
- Inhibitors of Protein Methyltransferases and Demethylases.Chemical reviews · 2018Review
- Epigenetic regulation of HIV-1 latency: focus on polycomb group (PcG) proteins.Clinical epigenetics · 2018Review
- Polycomb Repressive Complex 2 Methylates Elongin A to Regulate Transcription.Molecular cell · 2017Article
- Polycomb and Trithorax Group Genes inGenetics · 2017Review
- Structure of the PRC2 complex and application to drug discovery.Acta pharmacologica Sinica · 2017Review
- Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma.Cell reports · 2017Article
- Repo-Man/PP1 regulates heterochromatin formation in interphase.Nature communications · 2017Article
- The Role of the Histone Methyltransferase Enhancer of Zeste Homolog 2 (EZH2) in the Pathobiological Mechanisms Underlying Inflammatory Bowel Disease (IBD).The Journal of biological chemistry · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Polycomb repressive complex 2 (PRC2) is a conserved multisubunit enzyme that methylates histone H3 on lysine-27. This chromatin modification is a hallmark of target genes transcriptionally silenced by the Polycomb system. At its core, PRC2 activity depends upon the SET domain active site of its catalytic subunit, EZH2, as well as critical stimulatory inputs from noncatalytic subunits, especially EED and SU(Z)12. We review recent progress on this core PRC2 machinery, including key features of the active site, control mechanisms that operate via EZH2 phosphorylation, and subunit elements and architectures that influence PRC2 function. Among these, we highlight work identifying an EED regulatory site that enables PRC2 to bind pre-existing methylated H3-K27 and stimulate enzyme output. These advances illuminate basic inner workings of PRC2 and also provide insights that could aid design of PRC2 inhibitors. The chromatin landscape that PRC2 encounters in vivo is decorated with many histone modifications that accompany active transcription, such as H3-K4 methylation. It has long been assumed that these "active" modifications oppose PRC2 at some level but, until recently, mechanisms of this antagonistic cross-talk have been elusive. We discuss new findings that illuminate how H3-K4 and H3-K36 methylation, H3-K27 acetylation, and H3-S28 phosphorylation each exert a negative impact on PRC2 function. The emerging picture presents PRC2 as a cooperative multipart machine, intricately outfitted to sense and respond to the local chromatin environment and other cues. This PRC2 design ensures flexibility and fine tuning of its fundamental gene silencing roles in diverse biological contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.